CANDEL THERAPEUTICS, INC. Interest Expense Nonoperating
CANDEL THERAPEUTICS, INC. (CADL) reported Interest Expense Nonoperating of $1.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $1.57M, a 567.37% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.56M, a 411.11% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $1.42M, a 263.08% increase year-over-year.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $161.00K, a 66.94% decline year-over-year.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $2.12M, a 1.39% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $2.09M, a 19.46% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $2.60M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.57M 10-Q · filed 2026-08-13 | $3.14M 10-Q · filed 2026-08-13 | $4.55M derived: sum of 3 quarters · filed 2026-08-13 | $4.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-14 | $2.98M derived: sum of 2 quarters · filed 2026-05-14 | $3.14M derived: sum of 3 quarters · filed 2026-05-14 | $3.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.58M derived: sum of 2 quarters · filed 2026-03-12 | $1.81M derived: sum of 3 quarters · filed 2026-08-13 | $2.12M 10-K · filed 2026-03-12 |
| 2025-09-30 | $161.00K 10-Q · filed 2025-11-13 | $397.00K derived: sum of 2 quarters · filed 2026-08-13 | $703.00K 10-Q · filed 2025-11-13 | $1.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $236.00K 10-Q · filed 2026-08-13 | $542.00K 10-Q · filed 2026-08-13 | $932.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $306.00K 10-Q · filed 2026-05-14 | $696.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.18M derived: sum of 3 quarters · filed 2026-05-14 | $1.75M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $877.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.44M derived: sum of 3 quarters · filed 2026-03-12 | $2.09M 10-K · filed 2026-03-12 |
| 2024-09-30 | $487.00K 10-Q · filed 2025-11-13 | $1.05M derived: sum of 2 quarters · filed 2025-11-13 | $1.70M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $567.00K 10-Q · filed 2025-08-14 | $1.21M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $646.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $2.60M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |